Bicara Therapeutics (BCAX) Accounts Payables (2023 - 2026)

Bicara Therapeutics' Accounts Payables history runs 4 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 162.76% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 162.76% increase from a year earlier, with the FY2025 full-year figure at $400000.0, down 34.96% from the prior year.
• Accounts Payables grew to $6.2 million in Q1 2026 per BCAX's latest filing, from $400000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $6.2 million in Q1 2026 and bottomed at $400000.0 in Q4 2025.
• The 4-year median for Accounts Payables is $900000.0 (2023), against an average of $1.7 million.
• Across the five-year window, Accounts Payables sank 38.5% in 2024 and jumped 162.76% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $1.0 million in 2023, then sank by 38.5% to $615000.0 in 2024, then sank by 34.96% to $400000.0 in 2025, then soared by 1447.0% to $6.2 million in 2026.
• Per Business Quant, the three latest BCAX Accounts Payables figures stand at $6.2 million (Q1 2026), $400000.0 (Q4 2025), and $1.2 million (Q3 2025).